Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen s Q2 Revenues Jump 24 Percent; Announces Deals With Bayer, Genicon

NEW YORK, Aug. 6 – Qiagen on Monday reported a 24 percent surge in second-quarter revenues from the same period one year ago as demand for the company’s nucleic acid reagents and research tools continued to climb.

Revenue for the quarter ended June 30 totaled $66.0 million, up from $53.3 million during the second quarter 2000. Net earning for the recent period came in at $11.3 million, or 8 cents per share, compared with $1.8 million, or 1 cent er share, year over year.

A poll of seven analysts conducted by Thomson Financial/First Call indicated a consensus estimate of 6 cents per share.

The Venlo, Netherlands-based company spent $7.0 million on research and development during the second quarter 2001 compared with the $6.4 million it spent one year ago. Total expenses were greater in the second quarter 2000 reflecting Qiagen's $5.4 million acquisition of microarray developer Operon Technologies.

As of June 30, Qiagen had $17.8 million in cash, compared to $20.3 million at the end of March, and $24.0 million at the end of December. The company employs about 1,400 people worldwide.

Separately on Monday, Qiagen announced that Bayer has signed an early access agreement to use Qiagen’s Zeptogene technology workstation to perform gene-expression experiments using DNA microarrays. In June, Aventis Pharma agreed to use the PCR-free technology via an early-access agreement.

In another statement, Qiagen said that it had acquired the rights to exclusively distribute self-spotted microarray toolkit products that use Genicon’s Resonance Light Scattering (RLS) technology for analyzing self-spotted DNA microarrays. The companies did not disclose financial details.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.